On May 25, 2011, the Roskamp Institute and an international research consortium led by Trinity College Dublin, were selected for funding by the European Commission (EC) Seventh Framework Programme for a large-scale European clinical trial on Nilvadipine, an Alzheimer’s Disease drug developed at the Roskamp Institute.

More than 500 Alzheimer’s patients participated in the multicenter Phase III clinical trial designed to study the effectiveness of Nilvadipine. In their Sarasota laboratories, the research team discovered that Nilvadipine, a drug approved in Europe for treatment of hypertension, can stop the accumulation of the amyloid proteins in the brain – a development that has been implicated in Alzheimer’s disease.